Seeking Alpha

The FDA sends Genzyme a "refuse to file" letter in which it asks the Sanofi (SNY) unit to change...

The FDA sends Genzyme a "refuse to file" letter in which it asks the Sanofi (SNY) unit to change the presentation of the data in a filing for the firm's Lemtrada treatment for multiple sclerosis so that the application is easier to navigate. The FDA has not requested additional data for further studies for Lemtrada, which could be launched in 2013 if the FDA approves it. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)